• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.17% Nasdaq Down1.19%

    Spectrum Pharmaceuticals, Inc. (SPPI)

    7.16 Up 0.02(0.28%) Apr 28, 4:00PM EDT
    ProfileGet Profile for:
    Spectrum Pharmaceuticals, Inc.
    11500 South Eastern Avenue
    Suite 240
    Henderson, NV 89052
    United States - Map
    Phone: 702-835-6300
    Fax: 702-260-7405
    Website: http://www.sppirx.com

    Index Membership:N/A
    Full Time Employees:241

    Business Summary 

    Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkin’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB for treating breast, gastric, colorectal, and lung cancers; EOQUIN for non-muscle invasive bladder cancer; and SPI-2012 for chemotherapy-induced neutropenia in patients with breast cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. It has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., Ltd.; licensing and collaboration agreement with TopoTarget A/S; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Spectrum Pharmaceuticals, Inc.

    Corporate Governance 
    Spectrum Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Apr 1, 2016 is 10. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 9; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Rajesh C. Shrotriya M.D., 72
    Chairman and Chief Exec. Officer
    Mr. Joseph W. Turgeon , 58
    Pres and Chief Operating Officer
    Mr. Kurt A. Gustafson , 48
    Chief Financial Officer, Principal Accounting Officer and Exec. VP
    Mr. Shiv Kapoor ,
    VP of Strategic Planning & Investor Relations
    Mr. Bimal R. Shah ,
    VP of Fin. - Bus. Devel.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders